Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01950260 · ClinicalTrials.gov registry record · Phase 2
Early Levothyroxine Post Radioactive Iodine
A Phase 2 study, sponsored by Mayo Clinic.
- Completed
- Registry status
- Phase 2
- Development phase
- 61
- Enrollment target
NCT01950260: Completed Phase 2 study, sponsored by Mayo Clinic.
NCT01950260 is a Phase 2 study that has completed, run by Mayo Clinic. The registered enrollment target is 61 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01950260, a Phase 2 study, has completed, sponsored by Mayo Clinic.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 61 participants
- Enrollment target
Study Summary
The study will try to answer the question of whether early treatment with levothyroxine at 4 weeks after radioactive iodine for Graves'disease will prevent overt hypothyroidism (low thyroid hormone levels).
Interventions
- OTHER Placebo
- DRUG Levothyroxine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 61 participants |
| Start Date | 2013-09 |
| Est. Completion | 2017-04 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01950260
The ClinicalTrials.gov registry entry for NCT01950260 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 61 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Mayo Clinic, which has 2,844 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT01950260 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01950260 about?
NCT01950260 is a clinical study titled "Early Levothyroxine Post Radioactive Iodine". The study will try to answer the question of whether early treatment with levothyroxine at 4 weeks after radioactive iodine for Graves'disease will prevent overt hypothyroidism (low thyroid hormone levels).
What is the current status of trial NCT01950260?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 61 participants. The study started on 2013-09. Estimated completion is 2017-04.
What interventions are being tested in trial NCT01950260?
The interventions under investigation include: Placebo (OTHER), Levothyroxine (DRUG).
Who is sponsoring clinical trial NCT01950260?
This trial is sponsored by Mayo Clinic, which has 2,844 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.